NCT01592370 2025-10-22An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple MyelomaBristol-Myers SquibbPhase 1/2 Completed320 enrolled 35 charts
NCT04136756 2023-06-15NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin LymphomaNektar TherapeuticsPhase 1 Completed30 enrolled